Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Aug 25;5:PO.20.00494. doi: 10.1200/PO.20.00494

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 by American Society of Clinical Oncology

Creative Commons Attribution Non-Commercial No Derivatives 4.0 License: http://creativecommons.org/licenses/by-nc-nd/4.0/

PMC Copyright notice

FIG 4. — PFS analysis across RAF classes for two types of standard therapies commonly implemented in pancreatic cancer. PFS while receiving either (A) first-line FOLFIRINOX, (B) 5FU-based chemotherapy (10 on FOLFIRINOX; two on FOLFOX; two on FOLFIRI; four on 5FU/nal-irinotecan) in second-line or later, or gemcitabine/nab-paclitaxel given in (C) first line or (D) later lines were analyzed for each of the four categories of BRAF alterations with median PFS values (95% CIs) shown. FOLFIRI, fluorouracil, leucovorin, and irinotecan; FOLFIRINOX, infusional fluorouracil, leucovorin, irinotecan, and oxaliplatin; FOLFOX, infusional fluorouracil, leucovorin, and oxaliplatin; FU, fluorouracil; NA, not applicable; NR, not reached; PFS, progression-free survival.